• If you are wondering whether LeMaitre Vascular at around US$106 a share still offers value, you are not alone. A closer look at what that price really reflects can be useful.
• The stock has returned 17.3% over the last 30 days, 32.6% year to date and 28.5% over the past year, which may signal that expectations and perceived risk are shifting.
• Recent attention on LeMaitre Vascular has centered on how the company is positioned within medical devices and vascular care solutions, as investors compare it with peers in the same space. This context helps frame whether the recent share price moves align with business developments or simply changing sentiment toward the sector.
• Right now, LeMaitre Vascular has a value score of 1 out of 6. The next step is to look at the traditional valuation methods behind that score and then consider a broader way of thinking about value later in the article.

LeMaitre Vascular scores just 1/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: LeMaitre Vascular Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a business could be worth today by projecting its future cash flows and then discounting those back into today’s dollars.

For LeMaitre Vascular, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flows in US$. The latest trailing twelve month free cash flow is about $73.34 million. Analysts supply explicit free cash flow estimates for the earlier years, and Simply Wall St then extrapolates the later years, with projected free cash flow of $79.06 million in 2035.

Pulling these projections together and discounting them back, the DCF output suggests an intrinsic value of about $60.97 per share. Compared with a current share price around $106, this implies the shares trade at a premium of roughly 74.4% to that modeled value, so on this measure the stock screens as expensive rather than cheap.

Result: OVERVALUED

Our Discounted Cash Flow (DCF) analysis suggests LeMaitre Vascular may be overvalued by 74.4%. Discover 52 high quality undervalued stocks or create your own screener to find better value opportunities.

Approach 2: LeMaitre Vascular Price vs Earnings

For profitable companies, the P/E ratio is a useful check on value because it directly links what you pay per share to the earnings that support that price. It also captures how the market weighs factors like growth expectations and risk, with higher growth and lower perceived risk often justifying a higher P/E, and slower growth or higher risk usually pointing to a lower, more conservative range.

LeMaitre Vascular currently trades on a P/E of 41.94x, compared with the Medical Equipment industry average of about 27.45x and a peer average of 67.14x. Simply Wall St’s proprietary “Fair Ratio” for the company is 21.77x. This Fair Ratio is the P/E level that would typically be expected given LeMaitre Vascular’s earnings growth profile, profit margins, industry, market cap and risk characteristics.

The Fair Ratio is more tailored than a simple comparison with peers or the broad industry, because it adjusts for company specific factors rather than assuming all businesses deserve the same multiple. Setting the current 41.94x P/E against the 21.77x Fair Ratio suggests the shares trade above what this model would regard as a more balanced level.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your LeMaitre Vascular Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you turn your view of LeMaitre Vascular into a clear story that links assumptions about future revenue, earnings and margins to a forecast, a fair value, and finally a simple comparison between that fair value and the current price. Each Narrative sits on the Community page and updates automatically when new news or earnings arrive. One investor might build a cautious Narrative that leans toward the lower analyst fair values around US$92, while another might build an optimistic Narrative closer to US$120, and you can see both side by side to decide which story you find more reasonable.

Do you think there's more to the story for LeMaitre Vascular? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.